Amphilix AG

Amphilix AG is a Basel, Switzerland based biotech making bifunctional molecules to treat complex diseases using a proprietary linker platform. The linkers employ sophisticated 3D elements which allows the optimization of physicochemical and pharmacokinetic properties. Our lead project is a new First-in-Class targeted radioligand therapy for cancer for which we have teamed up with the Center of Radiopharmaceutical Sciences at the Swiss Federal Institute of Technology (ETH Zürich). Amphilix' drug target is highly expressed in cancer cells and in tumor-associated growing blood vessels and we have demonstrated selective uptake of our radioligand AMX-0053 within a mouse tumor model. The choice of target and use of the proprietary linker platform to optimize the radioligands fully differentiates Amphilix' product from those of other companies.